Most kidney cancers are found by accident on a scan before they cause any symptoms. Here is what that means, what happens next, and why early detection changes everything.
You went for an ultrasound for back pain, or a CT scan for something else entirely. The report mentions a mass in the kidney. Your doctor refers you to a urologist. You are now searching online at midnight, trying to understand what this means.
Let me explain clearly. A renal mass is not automatically cancer. And if it is cancer, finding it this way — before any symptoms appeared — is genuinely good news. Here is why.
The most common type of kidney cancer is Renal Cell Carcinoma (RCC) — cancer arising from the cells lining the tiny tubes within the kidney. There are several subtypes, of which clear cell RCC is the most common (about 75% of cases).
Other types include papillary RCC, chromophobe RCC, and oncocytoma — the last of which is actually benign (not cancer at all), though it can look similar on imaging.
RCC arises from the lining of the renal tubules — the tiny tubes that filter blood and produce urine. It typically forms as a single mass within one kidney, surrounded by normal kidney tissue. This is why partial removal is often possible.
Unlike bladder cancer which often announces itself with blood in urine, kidney cancer is characteristically silent. The classic triad of flank pain, blood in urine, and a palpable mass — which used to be how kidney cancer presented — is now seen in less than 10% of patients. When it appears, it usually means advanced disease.
Today, over 60% of kidney cancers are incidentally detected — found on an ultrasound or CT scan done for an unrelated reason. This is a genuine success story of modern medicine. A scan for back pain or a routine health check ultrasound identifies a small tumour before it has caused any harm.
Incidentally discovered kidney tumours are typically small (under 4 cm), confined to the kidney, and at an early stage. The 5-year survival for Stage I kidney cancer exceeds 90%. You did not miss this — the scan found it early, which is exactly when it is most curable.
A mass under 4 cm on a scan is called a small renal mass (SRM). An important fact: approximately 20–30% of small renal masses are benign — the most common being angiomyolipoma (containing fat, identifiable on CT) and oncocytoma (which requires biopsy or surgery to distinguish from cancer).
This means that before rushing to operate, characterisation is important. A contrast-enhanced CT or MRI with specific renal mass protocol can often determine the nature of the mass. Renal mass biopsy — a needle biopsy done under CT guidance — is increasingly used to confirm the diagnosis before surgery, particularly for small masses where active surveillance might be an option.
For small masses under 2 cm in older patients or those with significant comorbidities, active surveillance — regular scans to monitor growth rate — is a valid option. A mass that grows slowly or not at all over 12–18 months is unlikely to be aggressive. Your surgeon will discuss whether this applies to your situation.
Surgery remains the primary curative treatment for localised kidney cancer. There are two approaches — partial nephrectomy (removing just the tumour and a margin of normal tissue, preserving the rest of the kidney) and radical nephrectomy (removing the entire kidney). The decision depends on tumour size, location, and the function of the other kidney.
For small tumours in patients unfit for surgery, thermal ablation — destroying the tumour with heat (radiofrequency ablation) or cold (cryoablation) using a needle under CT guidance — is an option. Less invasive but with slightly higher local recurrence rates than surgery.
Metastatic RCC is treated with targeted therapies (sunitinib, pazopanib, cabozantinib) and immunotherapy (nivolumab, pembrolizumab combinations). Outcomes have improved dramatically over the past decade. Surgery to remove the primary tumour (cytoreductive nephrectomy) may still be considered in selected patients.
The kidneys filter waste products from the blood and regulate fluid balance. Losing one kidney reduces your total kidney function by approximately 50%. While most people can live normally with one kidney, reduced kidney function is associated with higher rates of cardiovascular disease, hypertension, and progression to chronic kidney disease over time.
Robotic partial nephrectomy — removing just the tumour and a margin of normal tissue — preserves kidney function while achieving the same cancer control as removing the entire kidney for tumours suitable for this approach. This is why, in experienced hands, partial nephrectomy is recommended for T1 tumours wherever technically feasible.
Robotic partial nephrectomy allows the surgeon to clamp the kidney's blood supply, remove the tumour precisely under 3D magnification, and repair the kidney — all within a narrow time window to minimise warm ischaemia time. This technical precision is significantly easier to achieve robotically than with open or standard laparoscopic surgery.
A kidney mass found on an incidental scan is frightening to receive — but it is one of the best outcomes of modern diagnostic medicine. Found early, kidney cancer is almost always curable. The priority is accurate characterisation of the mass, determination of stage, and a surgical plan that removes the cancer while preserving as much kidney as possible.
Ask your urologist specifically about partial nephrectomy — if it is technically feasible, it is the preferred option.
This article is written for general patient education and does not constitute personalised medical advice. Management of renal masses requires individual assessment by a qualified urological surgeon. Not all renal masses are cancer, and not all require immediate surgery.